Clinic
Waynesboro Hospital
Waynesboro Hospital was paid $1.48M by Medicaid between Jan 2018 and Dec 2024, across 71 billing codes. Its largest line is 99285, emergency room visit (most serious) — 34% of everything it billed.
33Billing provider infoWAYNESBORO HOSPITAL
WAYNESBORO, PA 17268
WAYNESBORO, PA 17268
33aNPI1821091059assigned 05/23/2005
33bProvider typeClinic/Center
28Total paid$1.48M
24GClaims41,223
24DCodes billed71
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Pennsylvania
Rank by total paid#63 of 176
Median peer was paid$441K
This provider vs. median3.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BUCZKOWSKI, LAURA controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16 | $12K | |
| 2019 | 72 | $1K | |
| 2020 | 4,321 | $137K | |
| 2021 | 21,139 | $737K | |
| 2022 | 6,580 | $247K | |
| 2023 | 6,541 | $252K | |
| 2024incomplete | 2,554 | $93K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 34% | 2,849 | 2,675 | $506K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 3,090 | 2,947 | $324K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 1,991 | 1,852 | $252K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.9% | 422 | 406 | $73K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 1,375 | 1,276 | $37K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 468 | 447 | $32K |
| 80053 | Comprehensive metabolic panel | 2.0% | 3,087 | 2,922 | $29K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.8% | 102 | 102 | $27K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 4,266 | 4,023 | $20K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 358 | 344 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 867 | 808 | $16K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 242 | 229 | $15K |
59 more codes
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 1,280 | $15K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 951 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 989 | $8K |
| 84702 | <1% | 517 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 129 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,130 | $7K |
| 84484 | <1% | 757 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 753 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 112 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 177 | $5K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 24 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 72 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 137 | $4K |
| 81001 | <1% | 1,385 | $4K | |
| 83690 | <1% | 726 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 426 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 232 | $3K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 58 | $2K |
| 85730 | <1% | 423 | $2K | |
| 87040 | <1% | 99 | $2K | |
| 85379 | <1% | 180 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 202 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 281 | $2K |
| 85610 | <1% | 553 | $1K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 97 | $1K |
| 80076 | <1% | 203 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 561 | $1K |
| 83605 | <1% | 191 | $1K | |
| 80051 | <1% | 210 | $1K | |
| 82565 | <1% | 215 | $983.45 | |
| 96376 | <1% | 27 | $867.48 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,303 | $849.83 |
| 84520 | <1% | 214 | $838.84 | |
| 82947 | <1% | 279 | $809.65 | |
| 73610 | <1% | 39 | $764.17 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 12 | $684.80 |
| 73630 | <1% | 56 | $639.57 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 37 | $533.01 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,393 | $484.14 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 64 | $451.69 |
| 83735 | <1% | 133 | $451.69 | |
| 87077 | <1% | 56 | $383.31 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,070 | $379.74 |
| 80061 | Lipid panel | <1% | 29 | $347.20 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 664 | $310.36 |
| 83880 | <1% | 12 | $237.13 | |
| 87186 | <1% | 29 | $234.40 | |
| 86140 | <1% | 62 | $155.85 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 28 | $128.31 |
| 81025 | <1% | 25 | $89.00 | |
| 82248 | <1% | 12 | $67.91 | |
| 86901 | <1% | 17 | $61.51 | |
| 86900 | <1% | 17 | $60.77 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 104 | $28.84 |
| 81003 | <1% | 21 | $26.36 | |
| A9270 | Non-covered item or service | <1% | 28 | $15.55 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 230 | $14.14 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 29 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUCZKOWSKI, LAURA (SR VP AND CFO)
| Provider | Location | Paid |
|---|---|---|
| Our Lady of Bellefonte Hospital INC | Ashland, KY | $12.13M |
| The Chambersburg Hospital | Chambersburg, PA | $10.29M |
| Vna Home Health Services | York, PA | $3.99M |
| Waynesboro Hospital | Fayetteville, PA | $831K |
| The Chambersburg Hospital | Chambersburg, PA | $801K |
| Wellspan Surgery and Rehabilitation Hospital | York, PA | $399K |
| Our Lady of Bellefonte Hospital INC | Ashland, KY | $200K |
| Waynesboro Hospital | Wayesboro, PA | $11K |
| The Chambersburg Hospital | Chambersburg, PA | $6K |
| The Chambersburg Hospital | Chambersburg, PA | $198.19 |
| Waynesboro Hospital | Waynesboro, PA | $6.58 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.